As far as we know, our study was the first to examine the genetic spectrums of icotinib-resistant NSCLC patients compared to other first generation EGFR TKIs, and found that SOX2 amplification were private to icotinib treatment resistance. Here, EGFR is linked to non-small cell lung carcinoma.